


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

2551-149

APPLICANT

BOSMAN et al.

FILING DATE

April 16, 2004

SERIAL NO.

10/825,219

GROUP

1648

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/AB/	Mushiake et al, "Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: Reevaluation of intravenous immunoglobulin replacement therapy", Biotherapy 7:101-107, 1994
/AB/	Hofstaetter et al, "S-Sulfonation: a Reversible Chemical Modification of Human Immunoglobulins Permitting Intravenous Application", Vox Sang. 45:155-165 (1983)
/AB/	Gronski et al, "S-Sulfonation: a Reversible Chemical Modification of Human Immunoglobulins Permitting Intravenous Application", Vox Sang. 45:144-154 (1983)
/AB/	Yamanaka et al, "Clinical Effect and Metabolism of S-Sulfonated Immunoglobulin in 7 Patients with Congenital Humoral Immunodeficiency", Vox Sang. 37:14-20 (1979)

*Examiner /Agnieszka Boesen/ Date Considered 07/22/2007

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)